SHANGHAI, Nov. 16, 2023 /PRNewswire/ VISEN Pharmaceuticals (VISEN), an innovative biopharmaceutical company focused on endocrine diseases, is pleased to
Mitochondrial Dysfunction May Raise Schizophrenia Risk in 22q Patients
A disorder called 22q11.2 deletion syndrome (22q) affects about one in 2,000 births, and causes dysfunction in every organ system including the heart and brain. It s been linked to behavioral changes including autism spectrum disorder, anxiety, and attention deficit hyperactive disorder. These problems may begin in adolescence and can persist in adults, when other psychiatric illnesses may emerge. Schizophrenia, for example, is about 25 times more likely in 22q patients.
Researchers have now learned more about a connection between an organelle known as the powerhouse of cells, the mitochondria, and the development of schizophrenia in 22q patients. The findings, which were reported in
E-Mail
Philadelphia, May 19, 2021 - A multidisciplinary team of researchers from Children s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania (Penn) showed how the batteries of cells are highly implicated in whether patients with the chromosome 22q11.2 deletion syndrome develop schizophrenia. The results of the study may eventually lead to targeted prevention and treatment strategies for patients with the condition.
The findings were published today in
JAMA Psychiatry.
22q11.2 deletion syndrome (22q) is a chromosomal difference that occurs in approximately one out of every 2,000 births and is associated with varying degrees of medical issues affecting every system in the body, including the developing heart, immune system, palate, and brain. 22q is also associated with behavioral health challenges such as attention deficit hyperactive disorder, autism spectrum disorder and anxiety. These symptoms can be observed during chil